A one-time asset sale boosted profits last quarter, but Q2 reveals a core business with thin margins and negative cash flow.
Colinz Laboratories reported a 12% yearly revenue rise in Q2 FY27, but profit collapsed 95% from the prior quarter. The plunge follows a one-off gain that flattered Q1 earnings, exposing ongoing margin pressure.
For a small pharmaceutical player like Colinz Labs, a quarter of explosive profit growth can be a mirage. The company’s September quarter shows why, as a 25% revenue jump was completely overshadowed by a 95% plunge in profit from the previous three months.
The headline numbers tell a story of divergence. Revenue grew 11.5% year-on-year to ₹1.55 crore. But profit fell 7.1% from a year ago to just ₹0.13 crore. The real shock is sequential: profit collapsed 94.6% from ₹2.4 crore in Q1.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 1.55YoY +12% | 1.24 | 1.39 |
| Profit (₹ Cr) | 0.13YoY -7.1% | 2.40 | 0.14 |
| Net Profit Margin | 8.4%YoY -18% | – | 10.2% |
This dramatic swing is not about operations. According to a report by scanx.trade, the previous quarter’s profit of ₹2.4 crore was inflated by a one-time gain of ₹2.76 crore from the sale of fixed assets. Strip that out, and the underlying profit trend is one of stagnation.
Even with that gain removed, profitability is under pressure. The net profit margin contracted by 180 basis points from a year ago to 8.4%. Scanx.trade notes that a higher tax provision and a 13% drop in other income squeezed the bottom line, even as pre-tax profit held flat.
Profit is one thing, but cash tells another story. For the first half of FY27, operating cash flow was negative, according to scanx.trade. This means the company’s modest profits are not yet translating into cash from its core business, a key sustainability risk for a small firm.
The broader market context offers little shelter. While the Indian pharmaceutical market saw strong growth, with gynaecology therapies up 16.6% in September according to Equirus Securities, Colinz Labs has not disclosed any major new orders or product launches to capture this demand.
Key Points
The quarter reveals a company caught between two narratives. The one-off gain in Q1 created an illusion of breakout profitability that Q2 sharply corrects. The core business, while generating modest revenue growth, operates on thin margins with profitability highly dependent on non-operational income.
The negative operating cash flow is a red flag, suggesting working capital pressures even at this small scale. With no visible capex plans or new product launches, the path to sustainable growth remains unclear. Investors are left weighing a cheap valuation—a P/E of 6.2 against an industry average of 49.5—against the fundamental challenge of building a scalable, cash-generative operation.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.